Everolimus-led treatment sequences deliver superior overall survival in metastatic clear cell renal cell carcinoma compared to strategies starting with other targeted therapies, according to research presented at IKCS: North America 2026.
Starting with Everolimus Extends Survival
- Sequence Matters: Starting kidney cancer treatment with everolimus rather than pazopanib or bevacizumab yields longer survival times.
- Beyond Initial Response: Tumors shrinking quickly in the beginning do not guarantee long-term survival advantages.
- Salvage-Aware Choices: Doctors should plan first- and second-line therapies together based on overall survival outcomes.
Phase 2 START Trial Findings
The phase 2 START trial (NCT01217931) assigned 175 patients with metastatic clear cell renal cell carcinoma (RCC) to one of six two-stage strategies. These strategies involved first- and second-line pairings of everolimus, pazopanib, and bevacizumab, Cancer Therapy Advisor reported.
Researchers designed the sequential multiple assignment randomized trial to compare overall survival between different sequences by including agents used as first salvage therapies. This approach avoided the confounding factors of non-randomized post-progression therapies typically seen in standard first-line trials.
Investigators used everolimus followed by pazopanib as the reference strategy in their analysis. They evaluated the strategies using Cox regression multivariate analysis adjusted for risk category and prior cytokine or vaccine therapy.
Over a median follow-up of 6.1 years, strategies utilizing everolimus first demonstrated the most favorable outcomes. The everolimus-then-pazopanib sequence achieved the longest median time to overall treatment failure at 25.4 months and the longest overall survival at a median of 70.6 months, Cancer Therapy Advisor reported.
The least favorable strategy tested was bevacizumab followed by pazopanib. This pairing yielded a time to overall treatment failure of 10.7 months and an overall survival of 32.3 months.
Patients receiving the bevacizumab-first sequence faced a significantly increased risk for overall treatment failure with a hazard ratio of 2.09. Their risk of death also rose significantly with a hazard ratio of 2.05, according to the trial data.
These survival advantages held true regardless of patient risk stratification. The results remained consistent whether risk was determined using the Memorial Sloan-Kettering Cancer Center score or the International Metastatic RCC Database Consortium risk criteria.
Initial Response Versus Long-Term Survival
Early response rates failed to identify the best treatment strategy for long-term survival. Treatment with pazopanib resulted in the highest objective response rate when used in the first line at 48.2%.
By comparison, first-line bevacizumab achieved an objective response rate of 10.9%. First-line everolimus recorded an objective response rate of 6.3%.
“Pazopanib-first strategies did not achieve the longest survival,” researchers noted regarding the discrepancy between initial tumor shrinkage and patient longevity.
“These findings support guiding sequencing decisions by salvage-aware OS rather than by early response,” the study authors concluded.
Contraindications & When to Consult a Doctor
Researchers listed no funding sources for this study and reported no conflicts of interest.
References
- ClinicalTrials.gov. Phase 2 START Trial (NCT01217931).
- IKCS: North America 2026 Scientific Presentations.